RAiSeDImplementation of Shared Decision Making in Rheumatoid Arthritis: A Stepped Wedge, Cluster-randomized Trial
Clinician communication training
+ Patient activation
+ RA Medication summary guide and RA Choice
Arthritis+6
+ Arthritis, Rheumatoid
+ Autoimmune Diseases
Services Research Study
Summary
Study start date: September 19, 2022
Actual date on which the first participant was enrolled.Background: Rheumatoid arthritis (RA) impacts quality of life causing disability in up to 1% of the population and 2% of those 60 and older. Men with RA have twice the risk of death as the general population. Treatment decisions after failure with first-line methotrexate are complex, involve trade-offs in terms of harm, and require individualized decisions. In shared decision making (SDM), patients and clinicians work together to identify how to best address the patient's situation. SDM has been proposed as a way to reduce disparities, but uptake is suboptimal and no effective tools to foster SDM in a systematic way across VA exist. Significance/Impact: Veterans with RA are disproportionately male, have more comorbidities, and higher mortality rates in comparison to the general population. SDM is the first principal of the RA treat to target guidelines. However, significant gaps in knowledge of effective interventions to support SDM exist - particularly in VA. This proposal is responsive to three VA HSR\&D priority domains: 1) health care value, 2) quality of health care, and 3) health equity. Innovation: Treatment studies in RA have focused primarily on white women, while men, who represent the VA RA population, have poorer outcomes. Targeting this subgroup to evaluate the impact of an SDM intervention on disease outcomes and adherence is novel. Use of a novel approach combining clinician training and a decision aid to recognize the unique needs of Veterans with RA is innovative. Specific Aims: Aim 1: Evaluate the effectiveness of a multi-component SDM intervention in a stepped-wedge, cluster-randomized controlled trial on improvement in disease activity, RA knowledge, and adherence. Hypothesis 1: During SDM intervention phases, Veterans will have lower disease activity compared to during control periods and will be more likely to experience clinically important differences in a standard disease activity index. Hypothesis 2: Veterans will have greater RA knowledge and better adherence after exposure to this intervention. Exploratory Hypothesis: The SDM intervention will have a greater effect in the likelihood of lowering disease activity among racial/ethnic minorities and Veterans with limited health literacy. Aim 2: Evaluate effectiveness of a multi-component intervention to facilitate SDM. Hypothesis: An SDM intervention for Veterans with RA will result in higher uptake of SDM in enrolled clinics during the intervention phase, relative to control phase. Aim 3: Conduct a qualitative evaluation of the SDM intervention and local implementation to inform future dissemination. Methodology: A stepped-wedge, cluster-randomized controlled trial design will be used to evaluate effectiveness of a novel SDM intervention across three sites. Participants: Veterans with RA and rheumatology clinicians; Intervention: multicomponent SDM intervention ; Control: participants at each site during the pre-intervention period; Outcomes: RA disease activity; patient-reported measures of adherence, knowledge, SDM, and an objective measure of SDM. Time: pre-intervention, intervention, and post-intervention phases for each step, measures collected over 42 months. Implementation/Next Steps: The proposed effectiveness study has the potential to speed the translation of SDM research within VA and nationally to improve quality of care for all persons with RA.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.792 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Services Research Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Inclusion criteria for patient participants (Aims 1 \& 2): * Meet administrative data definition of rheumatoid arthritis (see recruitment section) * Receive rheumatology outpatient care at participating clinics and seen at least once in prior 12 months * Age 18 years or older * English speaking * Moderate to high RA disease activity within 18 months prior to enrollment Inclusion criteria for professional participants (Aims 1-3): -Rheumatology attendings, fellows or advanced practice partners (nurse practitioners or physicians assistants) at the respective clinics Inclusion criteria for non-clinician participants (Aim 3): * Have held a leadership position within their respective institution for minimum of 12 months prior to enrollment * Have worked in the rheumatology clinic setting at their respective institution for minimum of 12 months prior Exclusion Criteria: Exclusion criteria for patient participants (Aims 1 \& 2): * Cognitive impairment * Inability to speak Exclusion criteria for professional participants (Aims 1-3): -none Exclusion criteria for non-clinician participants (Aim 3): * Have held a leadership position within their respective institution for \<12 months * Have worked in a clinic setting other than rheumatology * Have worked in a clinic setting \<12 months
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 4 locations
San Francisco VA Medical Center, San Francisco, CA
San Francisco, United StatesOpen San Francisco VA Medical Center, San Francisco, CA in Google MapsWilmington VA Medical Center, Wilmington, DE
Wilmington, United StatesVA Portland Health Care System, Portland, OR
Portland, United StatesCorporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, United States